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Cancer stem-like cells (CSC) represent a subpopulation of tumor cells with elevated 
tumor-initiating potential. Upon differentiation, they replenish the bulk of the tumor 
cell population. Enhanced tumor-forming capacity, resistance to antitumor drugs, and 
metastasis-forming potential are the hallmark traits of CSCs. Given these properties, it 
is not surprising that CSCs have become a therapeutic target of prime interest in drug 
discovery. In fact, over the last few years, an enormous number of articles describing 
compounds endowed with anti-CSC activities have been published. In the meanwhile, 
several of these compounds and also approaches that are not based on the use of 
pharmacologically active compounds (e.g., vaccination, radiotherapy) have progressed 
into clinical studies. This article gives an overview of these compounds, proposes a 
tentative classification, and describes their biological properties and their developmental 
stage. Eventually, we discuss the optimal clinical setting for these compounds, the need 
for biomarkers allowing patient selection, the redundancy of CSC signaling pathways 
and the utility of employing combinations of anti-CSC compounds and the therapeutic 
limitations posed by the plasticity of CSCs.
Keywords: cancer stem-like cells, epithelial–mesenchymal transition, therapy, biomarkers, classification, clinical 
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CANCeR STeM-LiKe CeLLS – ORiGiN, FUNCTiONAL 
PROPeRTieS, AND MARKeRS
Cancer stem-like cells (CSCs) represent a subpopulation of tumor cells. They are highly active in 
generating new tumors upon implantation in laboratory animals, while most tumor cells have low 
tumor-forming ability (1). CSCs are also resistant to conventional chemotherapeutics, radiation, 
and targeted therapies (2–4), and have enhanced metastasis-forming potential (5). Drug resistance 
allows CSCs to survive current therapies and to be ultimately responsible for relapse (4).
The first demonstration of the existence of CSCs was brought in acute myeloid leukemia 
(AML) (6). This initial observation was followed in ensuing year by similar observations in solid 
tumors (7–11).
The CSC population may not necessarily represent the original tumor-initiating cell (TIC) 
(12) and there is plasticity in the general tumor such that cells can loose and reacquire a CSC-like 
phenotype. Overall, it appears likely that, at any given time, CSCs are the result of the convergent 
action of two main events. The first is the genetic (mutations, rearrangements, and/or deregula-
tion of genes) and the epigenetic (microRNAs, alterations of the methylation profile of genes, or 
gene promoters) instability of tumor cells and the products that are expressed, e.g., oncogenes 
Epithelial tumor cell Mesenchymal tumor cell Cancer stem-like cell
Loss of epithelial markers
Acquisition of mesenchymal markers
Acquisition of cancer stem-like cell
markers/autophagy
Preservation of at least some
mesenchymal markers
FiGURe 1 | Transition from a Tumor Cell with a Predominantly epithelial Phenotype to a Tumor Cell with a Predominantly Mesenchymal Phenotype 
and to a Cancer Stem-Like Cell (CSC). The transition from a predominantly epithelial to a predominantly mesenchymal phenotype is better understood in 
molecular and phenotypic terms, but most available data suggest that a tumor cell with a predominantly mesenchymal phenotype must undergo several changes in 
order to acquire properties of a CSC, including autophagy. The heterogeneity of CSC populations suggests also the possibility of different transition states between 
a predominantly mesenchymal tumor cell and a CSC, in analogy with what has been observed for the transition between predominantly epithelial and mesenchymal 
tumor cells. See text for discussion and references to this point.
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(13, 14), or repressed as a consequence of this instability (15). 
The second event is represented by stimuli from the tumor 
microenvironment (TME). These stimuli are similar to those 
that promote the epithelial–mesenchymal transition (EMT) 
of tumor cells (16). Induction and maintenance of CSCs in 
response to these stimuli, however, is not a direct effect on 
tumor cells but, rather, the result of a cross-talk between 
different cell types within the TME that is largely effected by 
extracellular mediators released in response to the stimuli 
(17). Of note, genetic instability of tumor cells can also lead to 
overexpression of extracellular mediators (18, 19), which may 
add to those released in response to stimuli from the TME. 
The contribution of these two main events may differ quan-
titatively and qualitatively in different tumors and, over time, 
even within the same tumor, and this variability may underlie 
the plasticity and heterogeneity of CSCs. In fact, tumors may 
have a small number of CSCs, others a relatively large number, 
and still other tumors may even lack detectable CSCs (20, 21). 
Even within individual tumors, CSCs may express different, 
only partially overlapping phenotypes (22).
Given the multiplicity of genetic and environmental stimuli 
that are at the origin of CSCs, it is equally not surprising that 
a large number of signaling pathways have been reported being 
involved in the induction and maintenance of CSCs. Since CSCs 
and normal stem cells share a number of traits (4), it is logical 
that the role of signaling pathways involved in the physiology of 
normal stem cells, such as WNT, Notch, and Hedgehog (Hh), has 
been investigated with particular attention (4, 23).
THe ReLATiONSHiP BeTweeN eMT  
AND CSCs
CSCs can derive from bulk tumor cells that undergo an EMT, i.e., 
the conversion of tumor cells with an epithelial phenotype into 
cells with a mesenchymal phenotype (24, 25). EMT is critical for 
embryonic development and involves changes that lead to loss of 
cell–cell adhesion and cell polarity, with acquisition of migratory 
and invasive properties (26). In adults, EMT occurs during wound 
healing, tissue regeneration, organ fibrosis, and tumor progression 
(27). Tumor cells undergoing EMT are characterized by increased 
motility and invasiveness, resistance to antitumor drugs, and 
acquire tumor-initiating potential (28, 29). Reversal of EMT is 
accompanied by downregulation of CSC-associated traits (30). 
The question that obviously arises is whether tumor cells that have 
undergone an EMT are CSCs, i.e., if the two terms are interchange-
able. The question is not of mere academic interest because, in case 
of coincidence, therapeutic approaches aimed at targeting CSCs 
would be identical to those addressing EMT (31). Overall, there is 
considerable evidence for the two cell types not being coincident. 
Thus, it has been proposed that cells that have undergone an 
EMT acquire a CSC phenotype by engaging additional programs, 
such as the WNT and Hippo pathways (32). Furthermore, under 
certain circumstances, EMT and stemness can be uncoupled (33). 
Similarly, Thiery and coworkers have recently proposed that it 
is not solely the acquisition of EMT but the EMT stem cell-like 
phenotype that engenders drug resistance (34). In accordance 
with this view, it has been observed that the anti-CSC compound 
salinomycin (see below for more details on this compound) can 
cause cell death and decrease stem cell properties despite activa-
tion of EMT (35). Eventually, in many instances CSCs have been 
reported to be in a quiescent, autophagic state, that is the greatly 
different from mesenchymal-type tumor cells with enhanced 
invasive and migratory potential (36, 37). Blockade of autophagy 
has even been reported to reduce CSC activity (38). Overall, it 
seems that CSCs represent a further developmental stage that 
ensues after tumor cells have undergone EMT (Figure 1), and that 
autophagy may be a specific trait of such CSCs. CSCs, however, 
may not loose mesenchymal traits, as has been shown for circulat-
ing tumor cells (39).
ANTi-CSC COMPOUNDS iN CLiNiCAL 
DeveLOPMeNT
Search Criteria
A large number of compounds that have already received regula-
tory approval or are in clinical development have been tested 
TABLe 1 | Anti-CSC compounds targeting cell surface molecules.
Anti-CSC compound ClinicalTrials.gov identifier 
(phase for the indicated 
trials): patient population, 
CSC-related outcomes
Reference
Anti-clusterin mAb (AB-16B5) NCT02412462 (phase I): 
advanced solid tumors. 
Among outcomes: EMT and 
CSC biomarkers in circulating 
tumor cells and tumor biopsies
(45)
CXCR1 antagonist (reparixin) NCT02001974 (phase Ib, 
completed): HER2-negative 
metastatic breast cancer. 
Among outcomes: expression 
of ALDH1 and CD44 on tumor 
biopsies
(47)
Anti-ROR-1 mAb (cirmtuzumab/
UC-961)
NCT02222688 (phase I): 
relapsed or refractory CLL 
ineligible for chemotherapy
(48)
ALDH, aldehyde dehydrogenase; CLL, chronic lymphocytic leukemia; CRC, colorectal 
cancer; CSC, cancer stem-like cell; CXCR, CXC chemokine receptor; EMT, epithelial–
mesenchymal transition; HER, human epidermal growth factor receptor; mAb, 
monoclonal antibody; ROR-1, receptor tyrosine kinase-like orphan receptor 1; RSPO3, 
R-spondin-3.
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for their anti-CSC activity. The goal of this article, however, is 
to address those compounds that are in clinical development for 
their anti-CSC activity. In order to identify these compounds, 
a search was performed in the ClinicalTrials.gov website using 
the key word CSC. Of the almost 3,500 clinical trials that were 
recovered, however, only a minute fraction were actually dealing 
with CSCs, while the vast majority were on stem cells used for 
transplantation. In the following, we realized that the few studies 
that were directly dealing with CSCs were only a fraction of those 
investigating anti-CSC compounds. Some other studies were 
recovered using the key word TIC. It became clear, however, that 
many studies that were investigating anti-CSC compounds did not 
use the terms CSC or TIC and, therefore, could not be recovered. 
For this reason, we expanded the study, including pharmaceuti-
cal companies known to be involved in anti-CSC drug discovery. 
Eventually, we included also antitumor compounds that are not 
or not yet being developed as anti-CSC compounds, but whose 
anti-CSC activities have been confirmed in numerous preclinical 
studies. On the other hand, we excluded compounds that have 
already received regulatory approval for antitumor indications 
unrelated to CSCs, but which have recently been found to pos-
sess some selectivity for CSCs [e.g., Ref. (40)]. Admittedly, this 
approach is somewhat arbitrary but it has allowed to keep the 
number of anti-CSC compounds to be discussed in a manageable 
size while, nevertheless, addressing all main classes of anti-CSC 
compounds with one or more compounds being discussed for 
each class.
Anti-CSC Compounds Targeting 
extracellular Mediators or Cell 
Surface Molecules
In this section, we discuss compounds that target molecules that 
are extracellular mediators or are expressed on the surface of 
CSCs. Extracellular mediators and cell surface molecules that are 
part of complex signaling pathways involved in CSC biology and 
can be targeted at different levels of these pathways are discussed 
in later sections.
A large number of cell surface molecules that are expressed on 
CSCs of tumors or tumor subtypes of different tissue origin have 
been identified. CD44, CD47, CD33, CD133, CXC chemokine 
receptor (CXCR) 4, and CD26 are just some of these markers (41). 
Most of them are not CSC specific and in some cases may even be 
ubiquitously expressed, including blood cells (e.g., CD44, CD47) 
(42). Targeting these markers for therapeutic purposes may incur 
into severe side effects. Some CSC markers, however, have a more 
restricted expression and/or are overexpressed on CSCs, making 
them good potential targets for anti-CSC compounds. Recent 
approaches, such as the construction of bispecific antibodies, may 
offer, for the future, the opportunity to target also CSC markers 
that are broadly expressed (43).
Inhibitors of Clusterin
Clusterin is a stress-activated and apoptosis-associated 
molecular chaperone that protects cells from various stressors 
and is overexpressed in many human cancers (44). Antibodies 
targeting secreted clusterin inhibit transforming growth 
factor (TGF)-β-induced EMT in several tumor cell lines, without 
 affecting the  proliferation, and reduce lung metastasis in breast 
cancer and hepatocellular carcinoma (HCC) models (45, 46). 
Although no formal proof has been brought that anti-clusterin 
antibodies inhibit also CSCs, a humanized anti-clusterin mAb 
(AB-16B5) is being investigated in patients with solid tumors 
for clinical efficacy, and effects on EMT and CSC biomarkers 
(Table 1).
Inhibitors of CXCR1
Gene expression profiling of tumor cell lines that had been 
enriched for aldehyde dehydrogenase (ALDH)-positive CSCs 
identified interleukin (IL)-8 and its receptor CXCR1 as constitu-
tive of the CSC profile (49). IL-8 was also found to increase the 
number of ALDH-positive tumor cells and mammosphere for-
mation in vitro, an assay that reflects the tumor-initiating poten-
tial of cancer cells. Later, the same group showed that CXCR1 
blockade using either a CXCR1-specific blocking antibody or 
reparixin, a methanesulfonamide CXCR1 inhibitor, depleted the 
CSC population in two human breast cancer cell lines in  vitro 
(50) and targeted the CSC population in breast cancer xenografts, 
retarding tumor growth and reducing metastasis. Another work 
showed that this compound, in combination with paclitaxel, 
inhibited formation of brain metastases in a breast cancer model 
(47). This was likely the result of the combined effect of the two 
drugs, the pro-apoptotic action of paclitaxel and the cytostatic 
and anti-migratory effects of reparixin. Reparixin has been 
investigated in a clinical study in patients with human epidermal 
growth factor receptor (HER) 2-negative metastatic breast cancer 
(Table 1).
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Inhibitors of Receptor Tyrosine Kinase-Like 
Orphan Receptor 1
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type 
I orphan receptor, tyrosine kinase-like cell surface protein that is 
expressed during embryogenesis and is found on tumor cells of 
many different types of cancer, but not on normal adult tissues 
(51). ROR1 is preferentially expressed by less well-differentiated 
tumors with EMT-related markers that have high potential 
for relapse and metastasis. Silencing ROR1 in breast cancer 
cell lines attenuated expression of EMT-associated genes and 
impaired their metastatic potential in vivo (51). A recent study 
has reported that ROR1 is associated with ovarian cancer CSCs 
(48). Cirmtuzumab/UC-961, a humanized IgG1 mAb, binds 
with high-affinity ROR1, and inhibits migration in  vitro and 
engraftment in mice of patient-derived tumor cells that had been 
treated with the antibody (48). Cirmtuzumab is currently being 
investigated in patients with chronic lymphocytic leukemia who 
are ineligible for chemotherapy (Table 1).
Anti-CSC Compounds That Act on  
Ligand–Receptor Pairs and Their  
Signaling Pathways
Inhibitors of the TGF-β/TGF-β Receptor Pathway
The TGF-β/TGF-β receptor pathway is one of the most frequently 
involved in EMT and CSC biology. A recent study showed that 
blocking TGF-β signaling with a TGF-β type I receptor kinase 
inhibitor, EW-7197, suppressed paclitaxel-induced EMT and CSC 
functions, such as formation of mammospheres and ALDH activ-
ity, reduced the ratio of CD44+/CD24− CSCs, and CSC-associated 
transcription factors (52). Treatment with EW-7197 improved the 
efficacy of paclitaxel by decreasing the number of lung metastases 
and increasing survival time in vivo. The TGF-β pathway has also 
been shown to cross-talk with other signaling pathways involved 
in CSC biology, such as the Notch pathway (53). Thus, heightened 
Notch signaling in tumor cells magnified TGF-β-induced phos-
phorylation of signaling components and was required to sustain 
TGF-β-induced lung carcinoma cell growth. Conversely, Notch 
blockade reduced TGF-β signaling and limited lung carcinoma 
tumor progression. Overall, the TGF-β/TGF-β receptor signaling 
axis is involved in the CSC biology of several tumor types, such 
as breast cancer (54, 55), liver cancer (56), lung cancer (57), and 
head and neck cancer (53).
With regard to the clinical development of anti-TGF-β com-
pounds, it must be considered that TGF-β is a multifunctional 
cytokine and its inhibition leads to effects that are likely unrelated 
to EMT or CSC inhibition, such as enhancement of adaptive 
antitumor immune responses or normalization of the tumor 
stroma (58, 59). Nevertheless, several inhibitors of this pathway 
are now in clinical development, both anti-ligand antibodies 
(60) and inhibitors of the TGF-β receptor tyrosine kinase (RTK). 
One of the most frequently investigated for its anti-CSC activity 
is the TGF-β type I RTK inhibitor galunisertib/LY2157299. In a 
preclinical study, this compound blocked paclitaxel-induced CSC 
expansion in triple-negative breast cancer (TNBC) cell lines and 
mouse xenografts where the chemotherapeutic drug paclitaxel 
increased autocrine TGF-β signaling and IL-8 expression and 
enriched for CSCs (61). Moreover, treatment with LY2157299 
prevented reestablishment of tumors after paclitaxel treatment. 
The clinical development of this TGF-β inhibitor has been 
delayed owing to the detection of cardiovascular toxicity in 
preclinical studies (62, 63). This problem has now been bypassed 
through the application of judicious administration protocols 
(64). LY2157299 is now in several clinical trials although none of 
these trials explicitly refers to its anti-CSC activity (see Table 2).
Inhibitors of the Hedgehog Pathway
This signal transduction pathway, as well the WNT and Notch 
pathways are crucial for embryonic development. Therefore, 
compounds targeting these pathways may have negative con-
sequences on embryonic patterning and child development. 
Furthermore, these pathways are utilized in the generation of 
stem cells and in regenerative processes, and compounds acting 
on these pathways may have untoward effects on these processes 
(82). In spite of these concerns, an inhibitor of this pathway, 
vismodegib, has received regulatory approval (83).
In adult tissues, Hh signaling is relatively quiescent except in 
tissue maintenance and repair. Aberrant activation of Hh signal-
ing is implicated in multiple aspects of tumorigenesis, including 
maintenance of the CSC phenotype (84). Canonical Hh signaling 
is activated when a Hh ligand (Sonic Hh, Indian Hh, and Desert 
Hh) binds the transmembrane receptor Patched (PTCH) to relieve 
PTCH-mediated inhibition of the G-protein-coupled receptor-
like protein Smoothened (SMO). SMO then drives a signaling 
cascade that results in nuclear translocation and activation of 
the glioma-associated oncogene transcription factors (GLI). GLI 
activate transcription of genes regulating self-renewal, cell fate, 
survival, angiogenesis, EMT, and cell invasion.
Both ligand-dependent and ligand-independent mechanisms 
(instabilities of genes encoding individual components that 
lead to constitutive activation of the pathway) result in aberrant 
Hh pathway activation in cancer. Hh signaling associates with 
CSC biology in several types of hematological malignancies and 
solid tumors, such as pancreatic cancer (85), prostate cancer 
(86), glioblastoma (87), lung cancer (88), breast cancer (89), 
colon cancer (90), chronic myeloid leukemia (91), and multiple 
myeloma (92). Preferential activation of Hh signaling in CSCs 
compared with bulk tumor cells has been reported (88–90, 92) as 
well as upregulation of CSC markers (65, 89, 93). Several inhibi-
tors, mostly small-molecule inhibitors, of the Hh pathway are in 
clinical development for their antitumor effects. One of these, 
vismodegib, has already received regulatory approval. Some of 
these inhibitors, including vismodegib, are also being tested clini-
cally for their anti-CSC activity.
The first small molecule that was found to inhibit the Hh 
pathway is cyclopamine, a naturally occurring compound that 
belongs to the group of jerveratum alkaloids (94). Pharmaceutical 
companies have set out to develop cyclopamine derivatives with 
improved pharmacologic properties or new molecules showing 
improved binding to SMO, so far the main target for Hh pathway 
inhibitors. Vismodegib has been approved for the treatment of 
advanced basal cell carcinoma, where it induces a high percentage 
of response rates (95), but inevitably incurs into acquired resist-
ance (96). Vismodegib has demonstrated good efficacy also in 
TABLe 2 | Anti-CSC compounds that act on ligand–receptor pairs and their signaling pathways.
Anti-CSC compound ClinicalTrials.gov identifier (phase for the indicated trials): patient population, 
CSC-related outcomes
Reference
TGF-βIR TKI: galunisertib/LY2157299 NCT02240433, NCT02178358, NCT01246986 (phases Ib–II): in advanced hepatocellular 
carcinoma, alone or in combination with sorafenib
NCT02154646, NCT01373164 (phases Ib–II): with gemcitabine in unresectable pancreatic 
cancer
NCT02452008 (phase II): with enzalutamide in metastatic prostate cancer
NCT01220271, NCT01582269 (phases Ib–II): with radiochemotherapy or lomustine in 
malignant glioma
NCT02538471 (phase II): with radiotherapy in metastatic breast cancer
NCT02423343 (phase Ib/II): with anti-PD-1 (nivolumab) in different recurrent or refractory 
solid tumors
(61)
Hh-SMO inhibitor: vismodegib NCT01195415 (phase II, completed): with gemcitabine in advanced pancreatic cancer
Among outcomes: percent decrease of CD44+/CD24+ cells from biopsy
NCT01088815 (phase II): with gemcitabine and nab-paclitaxel in previously untreated 
metastatic pancreatic cancer. Among outcomes: changes in pancreatic CSCs
(65)
(66)
(67, 68)
Hh-SMO inhibitor: saridegib/IPI-926 NCT01255800 (phase I): with cetuximab in recurrent head and neck cancer (69)
(70)
Anti-RSPO3 mAb: OMP-131R10 NCT02482441 (phase Ia/Ib): in combination with chemotherapy in previously treated 
metastatic CRC
(71)
Anti-Frizzled receptors mAB: vantictumab/OMP-18R5 NCT01957007 (phase Ib): with docetaxel in patients with previously treated NSCLC
NCT02005315 (phase Ib): with Nab-paclitaxel and gemcitabine in untreated stage IV 
pancreatic cancer
NCT01973309 (phase Ib): with paclitaxel in locally recurrent or metastatic breast cancer
(72)
Frizzled 8 receptor-IgG1 Fc fusion: ipafricept/OMP-54F28 NCT02092363 (phase Ib): with paclitaxel and carboplatin in recurrent platinum-sensitive 
ovarian cancer
(73)
WNT, inhibitor of the interaction β-catenin-TCF: 
CWP232291 Undisclosed structure
NCT02426723 (phase Ia/Ib): alone or with lenalidomide and dexamethasone in relapsed or 
refractory multiple myeloma
NCT01398462 (phase I): in various relapsed or refractory hematological malignancies
(74)
Inhibitor of the interaction β-catenin-TCF: PRI-724 NCT01764477 (phase Ib): in advanced or metastatic pancreatic cancer eligible for second-
line therapy
NCT02413853 (phase II): with or without chemotherapy/anti-VEGF mAb as first line 
treatment for metastatic CRC
NCT01606579 (phase I/II): in advanced myeloid malignancies
(75)
(76)
Inhibitor of the interaction β-catenin–mucin-1: GO-203-2C 
Ac-(d)Arg-(d)Arg-(d)Arg-(d)Arg-(d)Arg-(d)Arg-(d)Arg-(d)Arg-(d)
Arg-(d)Cys-(d)Gln-(d)Cys-(d)Arg-(d)Arg-(d)Lys-(d)Asn-NH2 
disulfide
NCT02204085 (phase I/II): in relapsed or refractory AML. Among outcomes: assess 
whether GO-203-2c is effective in targeting mucin-1-C overexpressing AML progenitor 
cells, in decreasing engraftment potential of AML progenitor cells
(77)
(78)
(Continued)
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Anti-CSC compound ClinicalTrials.gov identifier (phase for the indicated trials): patient population, 
CSC-related outcomes
Reference
Notch, anti-DLL4 mAb: demcizumab/OMP-21M18 NCT01189929, NCT02289898 (phases Ib–II): with gemcitabine ± Abraxane® in pancreatic 
cancer. Among outcomes: assessment of exploratory biomarkers
NCT01952249 (phase Ib/II): with paclitaxel in platinum-resistant ovarian, peritoneal, or 
fallopian tube cancer
NCT01189968, NCT02259582 (phase Ib-II): with carboplatin and pemetrexed in non-
squamous NSCLC. Among outcomes: assessment of biomarkers
NCT01189942 (phase Ib): with chemotherapy as first- or second-line treatment metastatic 
CRC. Among outcomes: assessment of biomarkers
(79)
Notch, bispecific anti-DLL4 x anti-VEGF mAb: 
OMP-305B83
NCT02298387 (phase I): dose escalation and expansion study in solid tumors
Anti-Notch 2/3 mAb: tarextumab/OMP-59R5 NCT01859741 (phase Ib/II): with etoposide and platinum therapy in untreated extensive 
stage SCLC
NCT01647828 (phase Ib/II): with nab-paclitaxel and gemcitabine in untreated stage IV 
pancreatic cancer
(30)
Anti-Notch 1 mAb: brontictuzumab/OMP-52M51 NCT01778439 (phase I): dose escalation study in solid tumors
NCT01703572 (phase I): dose escalation study in lymphoid malignancies
Anti-DLL3 ADC: rovalpituzumab tesirine/SC16LD6.5 NCT01901653 (phase I/II): dose escalation study of safety, pharmacokinetics, and 
preliminary efficacy in recurrent SCLC
(80)
Anti-Ephrin A4 ADC: PF-06647263 NCT02538471 (phase I): dose escalation, safety, and pharmacokinetics study in advanced 
solid tumors
(81)
ADC, antibody-drug conjugate; AML, acute myeloid leukemia; CRC, colorectal cancer; CSC, cancer stem-like cell; CXCR, CXC chemokine receptor; DLL, Delta-like ligand; 
EMT, epithelial–mesenchymal transition; Fc, fraction crystallizable; Hh, Hedgehog; IgG, immunoglobulin G; mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; PD, 
programed cell death; SMO, smoothened; TCF, T-cell factor; TGF-βIR, transforming growth factor-βI receptor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
TABLe 2 | Continued
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medulloblastoma (97), but only limited activity in other tumor 
types. This lack of activity may be due to many factors, but the 
possibility of a tumor type-dependent redundancy of signaling 
pathways appears a likely possibility.
In preclinical studies, vismodegib inhibited cell viability and 
induced apoptosis in three pancreatic cancer cell lines and pan-
creatic CSCs (66). Suppression of both GLI1 plus GLI2 mimicked 
the changes in cell viability, spheroid formation, apoptosis, and 
gene expression observed in vismodegib-treated pancreatic 
CSCs. In another study, vismodegib decreased spheroid and 
colony formation of gastric cancer cell lines with upregulated 
CD44 and Hh pathway proteins (65). CD44-positive cells were 
more resistant to chemotherapeutics, showed enhanced migra-
tion, invasion, and anchorage-independent growth, and these 
properties were reversed by vismodegib. Vismodegib is being 
investigated in two phase II clinical studies for its anti-CSC activ-
ity. In both, vismodegib is studied in advanced pancreatic cancer 
in combination with chemotherapeutics (Table 2). Results of one 
of these studies have been published (67). Treatment for 3 weeks 
led to down-modulation of GL1 and PTCH1 and decreased 
fibrosis, but no significant changes in CSCs were observed, and 
combined treatment with vismodegib and gemcitabine was not 
superior to gemcitabine alone.
Saridegib/IPI-926 is another SMO inhibitor that is in clinical 
investigation (69). It is being studied in combination with the 
anti-epidermal growth factor receptor (EGFR) mAb cetuximab 
in recurrent head and neck cancer patients (Table 2). Preliminary 
results of this study have now been published (70). Among eight 
evaluable patients, the best responses were one partial response, 
four stable diseases, and three disease progressions. Decreases in 
tumor size were seen in both cetuximab-naïve patients. Toxicities 
were as expected. Tumor shrinkage and progression-free survival 
were associated with downregulation of intra-tumoral Hh path-
way gene expression during therapy.
Inhibitors of the WNT Pathway
WNT proteins are a large family of secreted molecules that play a 
critical role in the development of various organisms (98). In the 
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absence of extracellular WNT molecules, a destruction complex, 
including the proteins adenomatous polyposis coli (APC), gly-
cogen synthase kinase 3β (GSK3β) and AXIN, phosphorylates 
β-catenin, targeting it for ubiquitylation and degradation. The 
binding of WNTs to Frizzled receptors and the co-receptors low-
density lipoprotein receptor-related protein 5 (LRP5) and LRP6, 
transmits a signal through Dishevelled, which results in inhibi-
tion of the destruction complex and nuclear entry of β-catenin. 
In the nucleus, β-catenin acts as a bridge between members of 
the T cell factor (TCF) family of transcription factors and the 
basal  transcriptional apparatus via co-activators [CREB-binding 
protein (CBP), E1A-associated protein p300, the co-activator 
Pygopus, B cell lymphoma 9, etc]. Aberrant activation of the 
WNT/β-catenin signaling pathway has recently been implicated 
in several types of human cancers (82), and shown to play a criti-
cal role in CSC biology (99, 100). Moreover, aberrant activation 
of the transcriptional activity of β-catenin, independently of 
upstream WNT signaling, has been associated with breast CSC 
amplification and tumorigenesis (101).
Inhibitors of the WNT pathway may act at different levels of 
the signaling chain. One approach is to act on ligands of this path-
way. R-spondins (RSPOs) are secreted proteins that potentiate 
canonical WNT signaling (102). Translocations of RSPO genes 
are recurrent in a subset of colorectal tumors. PTPRK–RSPO3 is 
one of the fusions that can originate from these translocations. 
It has recently been shown that targeting RSPO3 in PTPRK–
RSPO3-fusion-positive human tumor xenografts inhibits tumor 
growth and promotes differentiation (71). Genes expressed in the 
stem-cell compartment of the intestine were among those most 
sensitive to anti-RSPO3 treatment. A clinical study with the anti-
RSPO3 mAb OMP-131R10 is ongoing in advanced solid tumors 
and in metastatic colorectal cancer (Table 1).
Another approach has been to raise inhibitory mAbs against 
Frizzled receptors. This is a challenging undertaking since there are 
19 human WNTs and 10 Frizzled receptors. Nevertheless, a mAb, 
vantictumab/OMP-18R5, which binds to five distinct Frizzled 
receptors through a conserved epitope, has been obtained (72). 
In xenograft studies with minimally passaged human tumors, this 
antibody inhibited the growth of a range of tumor types, reduced 
tumor cell proliferation, and CSC frequency. Strong synergy was 
observed with several chemotherapeutics. Vantictumab is now 
being investigated in several phase I clinical trials in combination 
with chemotherapeutics in patients with advanced solid tumors 
(Table 2).
The fusion protein ipafricept/OMP-54F28 encompasses a por-
tion of the Frizzled 8 receptor fused to the Fc portion of IgG1. This 
protein competes with the native Frizzled 8 receptor for its ligands 
and antagonizes WNT signaling. In preclinical models, OMP-
54F28 reduced tumor growth and decreased CSC frequency as a 
single agent and in combination with chemotherapeutics (73). A 
phase Ia clinical study is nearing completion with this compound 
in advanced solid tumors and phase Ib studies have been started 
in combination with chemotherapeutics in ovarian, pancreatic, 
and hepatocellular cancers (Table 2).
Organic molecules have been synthesized that antagonize 
the binding of β-catenin to the TCF protein or to transcrip-
tional co-activators. These molecules cause downregulation of 
β-catenin-responsive genes. CWP232228 inhibits the interaction 
of β-catenin with TCF (74), and this was shown to inhibit the 
growth of both breast CSCs and bulk tumor cells, but breast CSCs 
exhibited greater sensitivity. CWP232228 treatment blocked also 
secondary xenograft tumor development and inhibited metasta-
sis formation. CWP232228 is not being investigated in clinical 
studies, but an undisclosed, but probably closely related molecule 
(CWP232291) is now in phase I clinical studies for the treatment 
of hematological malignancies (Table 2).
PRI-724 is a small molecule that inhibits the interaction 
between β-catenin and CBP. PRI-724 sensitized ovarian cancer 
cells to cisplatin and decreased tumor sphere formation (75). 
Importantly, CBP/β-catenin antagonists appear to have the abil-
ity to safely eliminate CSCs by taking advantage of an intrinsic 
differential preference in the way somatic stem cells and CSCs 
divide (76). PRI-724 is currently in phase I/II clinical trials for 
the treatment of solid tumors and hematological malignancies 
(Table 2).
Still another approach to interfere with this pathway is to 
inhibit the interaction between mucin 1 and β-catenin. Mucin 
1 is a membrane-bound glycoprotein expressed by most glan-
dular and ductal epithelial cells, and is overexpressed in many 
diverse human carcinomas. The mucin 1–β-catenin interaction 
is stabilized by extracellular matrix protein 1 and leads to the 
upregulation of EMT- and CSC-related genes (77, 78). The 
mucin 1 inhibitor GO-203-2C is a highly cationic peptide with a 
polyarginine tail at the N-terminus. It interacts with the mucin 1 
C-terminus on the cell surface and inhibits cell–cell interactions 
and signaling. It is currently in a phase I/II trial in patients with 
relapsed or refractory AML (Table 2).
Several other small-molecule WNT/β-catenin signaling 
inhibitors have been developed and are in development [listed 
in Ref. (74)], but so far no direct evidence has been brought 
that these molecules inhibit CSCs, although this appears a likely 
possibility.
Inhibitors of the Notch Pathway
The Notch pathway regulates cell fate specification, tissue pattern-
ing, and cellular survival. In mammals, the Notch signaling system 
consists of five membrane-bound ligands, DLL1, 3, 4, and Jagged 
1, 2, and four single-pass transmembrane receptors, Notch1–4. 
Ligand binding to Notch triggers the proteolytic activation of 
the receptor and translocation of its intracellular domain to the 
nucleus, where it interacts with the CSL transcription factor to 
regulate the expression of target genes (103). Notch signaling is 
involved in normal development and in most organs, including 
the hematopoietic system and the vasculature (103). Alterations 
in the Notch signaling pathway stimulate proliferation, restrict 
differentiation, promote cellular survival, and are associated with 
oncogenesis in several malignancies. Notch plays a critical role 
in CSC biology (86). Of the Notch ligands, DLL4 is commonly 
expressed in solid tumors and associated with chemoresistance. 
DLL4 binds all four Notch receptors, but the interaction with 
Notch 1 is preferred (103).
Several approaches are being pursued for inhibition of Notch 
signaling. A first has been to inhibit Notch receptor cleavage 
by γ-secretase inhibitors (104). The therapeutic utility of these 
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compounds, however, is limited due to intestinal toxicity result-
ing from pan-Notch inhibition (105). One γ-secretase inhibitor 
(RO4929097) was being studied in clinical trials for its antitumor 
and anti-CSC activity in breast cancer, but its development has 
now been discontinued.
A second approach has been to generate mAbs that inhibit 
Notch signaling. A humanized IgG2 anti-DLL4 mAb, demci-
zumab/OMP-21M18, is now in clinical investigation as anti-CSC 
compound (79) (Table 2). In human tumor models, both alone 
or in combination with chemotherapy, it reduced tumor growth, 
regrowth, and number of CSCs. A phase I clinical trial has 
allowed defining a recommended phase 2 dose. Moreover, 16 of 
25 (64%) evaluable patients at one dose (10 mg/kg) had evidence 
of disease stabilization or response (79). Results suggested also 
that the antitumor effects of demcizumab might be the result 
of a combination of anti-CSC and anti-angiogenic effects, an 
observation consistent with the role of Notch signaling in normal 
angiogenesis (106) and tumor angiogenesis (107).
Given the role of Notch signaling in tumor angiogenesis, it is 
not surprising that other anti-DLL4 mAbs are in clinical inves-
tigation as inhibitors of tumor angiogenesis (e.g., enoticumab) 
(108). In fact, one compound in clinical development has been 
designed to optimally exploit both anti-angiogenic and anti-CSC 
activities. This is OMP-305B83, a bispecific anti-DLL4 and anti-
vascular endothelial growth factor (VEGF) mAb that is currently 
in phase I clinical studies (Table 2).
In addition to inhibit the activity of Notch ligands, another 
possibility is to inhibit this pathway with anti-receptor (anti-
Notch) antibodies. In order to avoid pitfalls deriving from 
pan-Notch inhibition, a novel mAb, tarextumab/OMP-59R5, has 
been generated that blocks the function of Notch 2 and Notch 
3 (30). OMP-59R5 reduced CSC frequency in combination 
with chemotherapeutic agents in various cancer models, and 
the triple combination of anti-Notch2/3 with gemcitabine plus 
nab-paclitaxel produced striking tumor regression in pancreatic 
cancer xenografts. OMP-59R5 is now in phase I clinical trials 
(Table 2). Still another mAb that is in clinical trials binds only the 
Notch1 receptor (brontictuzumab/OMP-52M51). It is employed 
only for patients that demonstrate tumor overexpression of the 
activated form of Notch1. For this purpose, patients’ tumors are 
prescreened by immunohistochemistry to determine eligibility 
(Table 2).
A special role in the Notch pathway is played by DLL3. DLL3 
predominantly localizes to the Golgi apparatus and is unable to 
activate Notch signaling (109). In the course of normal develop-
ment, DLL3 inhibits Notch pathway activation by interacting with 
Notch and DLL1 and redirecting or retaining them to the late 
endosomal/lysosomal compartments or in the Golgi, respectively, 
thereby preventing their localization to the cell surface (110). 
DLL3 is overexpressed and relocalizes to the surface of small cell 
lung cancer (SCLC) and large cell neuroendocrine carcinoma 
cells (80). A DLL3-targeted antibody-drug conjugate (ADC), 
rovalpituzumab tesirine/SC16LD6.5, encompassing a humanized 
anti-DLL3 mAb conjugated to a DNA-damaging pyrrolobenzo-
diazepine dimer was synthesized and found to induce durable 
tumor regression in  vivo across multiple patient-derived xeno-
graft models. Lack of tumor recurrence resulted from effective 
targeting of DLL3-expressing CSCs. In vivo efficacy correlated 
with DLL3 expression, and responses were observed in xenograft 
models independently of their sensitivity to standard-of-care 
chemotherapy regimens. This ADC is now being investigated in 
a phase I/II clinical trial in patients with SCLC (Table 2).
Inhibitors of the Ephrin/Ephrin Receptor Pathway
Ephrin receptors comprise the largest family of RTKs in the 
human genome and modulate signaling pathways that impact cell 
fate decisions during embryogenesis and adult tissue homeostasis 
(111). Numerous therapeutics targeting this pathway are being 
tested in clinical trials; the majority are tyrosine kinase inhibitors. 
Vast functional redundancy within the Ephrin/Ephrin receptor 
pathway likely compromises the effect of blocking specific Ephrin 
ligands, while pan-Ephrin inhibition is toxic (111).
Gene expression analysis of breast and ovarian CSCs identi-
fied Ephrin A4 as a potential therapeutic target (81). An ADC 
targeting Ephrin A4 has been generated in order to induce 
cell death upon internalization, thereby avoiding redundancy 
of this highly diverse ligand–receptor family, and delaying the 
insurgence of resistance. This conjugate, labeled PF-06647263, 
encompasses a humanized anti-Ephrin A4 mAb conjugated to 
the DNA-damaging agent calicheamicin. It achieved sustained 
tumor regressions in both TNBC and ovarian cancer xenografts 
in  vivo (81). Non-claudin low TNBC tumors exhibited higher 
expression and more robust responses than other breast cancer 
subtypes. PF-06647263 is currently being evaluated in a phase I 
clinical trial.
Anti-CSC Compounds That inhibit  
Post-Receptor Signaling Pathways
Inhibitors of SRC and Focal Adhesion Kinase
SRC and focal adhesion kinase (FAK) are two interacting 
membrane-proximal tyrosine kinases. Both can be activated by 
adhesion receptors, RTKs, and cytokine receptors. Increased SRC 
and FAK phosphorylation and activity are upregulated in many 
cancers and have been implicated in several aspects of cancer 
progression. Both of these tyrosine kinases have been implicated 
in CSC biology. SRC has been reported being involved in CSC 
biology of, for example, hepatic cancer (112), pancreatic cancer 
(113), and breast cancer (114); FAK in breast cancer (115) and 
squamous cell carcinoma (116).
Several SRC and FAK inhibitors are in clinical studies. Some 
of these studies are centered on their anti-CSC activity. Dasatinib 
is a non-specific SRC inhibitor that inhibits also the Bcr/Abl 
tyrosine kinase. It has been approved for the treatment of chronic 
myeloid leukemia and Philadelphia chromosome-positive acute 
lymphoblastic leukemia. Dasatinib was shown in a clinical study 
to induce a long-standing decrease of leukemic stem cells in 
patients with CML (117). It is unclear, however, whether this 
effect is the result of Bcr/Abl inhibition in this patient population 
or whether the decrease is the result of inhibition of both tyrosine 
kinases. Dasatinib is being studied in a phase II clinical trial for 
the depletion of CSCs in CML patients (Table 3).
Two FAK inhibitors that have been originated by the same 
company are now in clinical investigations for their antitumor 
and anti-CSC activity: defactinib/VS-6063/PF-04554878 and 
TABLe 3 | Anti-CSC compounds that inhibit post-receptor signaling pathways.
Anti-CSC compound ClinicalTrials.gov identifier (phase for the indicated trials): patient population, CSC-related 
outcomes
Reference
SRC inhibitor dasatinib NCT00852566 (phase II): comparing depletion of CSCs with dasatinib vs. imatinib in newly diagnosed 
chronic myeloid leukemia
(117)
FAK inhibitor: defactinib/VS-6063/
PF-04554878
NCT01951690 (phase II): in KRAS mutant NSCLC. Phase II. Among outcomes: association between 
pharmacodynamic biomarkers and clinical outcome
NCT01943292 (phase I): dose escalation to evaluate safety and pharmacokinetics in non-hematologic 
malignancies
NCT01778803 (phase I/Ib): with paclitaxel in advanced ovarian cancer. Among outcomes: association 
between pharmacodynamic biomarkers and clinical outcome
NCT02004028 (phase II): in surgical resectable malignant pleural mesothelioma. Among outcomes: 
biomarker responses in tumor tissue
NCT00787033 (phase I): dose escalation to evaluate safety, pharmacokinetics, pharmacodynamics in 
advanced non-hematologic malignancies
(118)
(119)
FAK inhibitor: VS-4718 NCT01849744 (phase I): in metastatic non-hematologic malignancies. Among outcomes: correlation of 
biomarkers (phospho-FAK, CSCs) with response to VS-4718 therapy
NCT02651727 (phase I): with Nab-paclitaxel and gemcitabine in advanced cancers
(120)
PI3K/mTOR dual inhibitor: VS-5584 NCT01991938 (phase I): dose-escalation study in advanced non-hematologic malignancies or lymphoma. 
Among outcomes: correlation of tumor genetic alterations and/or biomarkers with response to therapy
NCT02372227 (phase I): with FAK inhibitor VS-6063 in relapsed malignant mesothelioma
(121)
mTOR inhibitor temsirolimus NCT00949325 (phase I/II): with liposomal doxorubicin in advanced soft tissue and bone sarcomas (122)
MEK inhibitor: trametinib/GSK1120212 NCT01553851 (phase II): in surgically resectable oral cavity squamous cell cancer. Among outcomes: tumor-
specific changes in putative CD44+ CSCs and intracellular phospho-extracellular signal-regulated kinase 1/2 
staining after treatment
(123)
(Continued)
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Anti-CSC compound ClinicalTrials.gov identifier (phase for the indicated trials): patient population, CSC-related 
outcomes
Reference
STAT3 inhibitor: Napabucasin/BBI608 NCT02178956 (phase III): with paclitaxel vs. placebo + paclitaxel in gastric and gastro-esophageal junction 
cancer
NCT01830621 (phase III): BBI608 and best supportive care vs. placebo and best supportive care in patients 
with pretreated advanced CRC
NCT02315534 (phase Ib/II): with temozolomide in recurrent or progressed glioblastoma. Among outcomes: 
assessment of CSCs after tumor biopsy
NCT02467361 (phase Ib/II): with immune checkpoint inhibitors to adult patients in advanced cancers. Among 
oucomes: CSC assays on biopsied patient tumor tissue
NCT01325441 (phase Ib/II): with paclitaxel in advanced malignancies
NCT02352558 (phase Ib): in advanced, refractory hematologic malignancies. Among outcomes: CSC assays 
on patient samples
NCT02024607 (phase Ib): with standard chemotherapies in adult patients with advanced gastrointestinal 
cancer. Among outcomes: effect on CSCs determined by immunohistochemistry
NCT01775423 (phase I): in advanced malignancies
NCT02231723 (phase I): with gemcitabine and nab-paclitaxel or chemotherapy combination in pancreatic 
cancer. Among outcomes: CSC assays on biopsied tumor tissue
(124)
Inhibitor of Nanog and other targets: 
BBI503 undisclosed structure
NCT02432690 (phase II): in asymptomatic recurrent ovarian cancer patients with CA-125 elevation
NCT02232646 (phase II): in advanced urologic malignancies. Among outcomes: pharmacodynamics on 
biopsied patient tumor tissue
NCT02232633 (phase II): in advanced hepatobiliary cancer. Among outcomes: pharmacodynamics on 
biopsied patient tumor tissue
NCT02232620 (phase II): in advanced gastrointestinal stromal tumors. Among outcomes: 
pharmacodynamics on biopsied patient tumor tissue
NCT02483247 (phase Ib/II): with selected anti-cancer therapeutics in adults with advanced cancer. Among 
outcomes: CSC assays on biopsied patient tumor tissue
NCT01781455 (phase I): in advanced solid tumors. Among outcomes: effect on CSCs through 
immunogistochemistry
NCT02432326 (phase Ib): BBI608 and BBI503 in advanced solid tumors
NCT02279719 (phase Ib/II): BBI608 with sorafenib, or BBI503 with sorafenib in hepatocellular carcinoma. 
Among outcomes: CSC assays on biopsied patient tumor tissue.
(125)
AMPK activator metformin NCT01442870 (phase I): clinical safety of combining metformin with anti-cancer chemotherapy
NCT01579812 (phase II): targeting CSCs for the prevention of relapse in stage IIC/III/IV ovarian, fallopian 
tube, and primary peritoneal cancer
NCT01717482 (phase II). Metformin for chemoprevention in NSCLC. Among outcomes: metformin sensitivity 
in induced pluripotent stem cells
(126)
(127)
(128–133)
AMPK, 5′ adenosine monophosphate-activated protein kinase; CRC, colorectal cancer; CSC, cancer stem-like cell; FAK, focal adhesion kinase; mTOR, mammalian target of 
rapamycin; NSCLC, non-small cell lung cancer; PI3K, phosphoinositide 3-kinase; STAT, signal transducer and activator of transcription.
TABLe 3 | Continued
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VS-4718. These are all small-molecule tyrosine kinase inhibitors. 
Results of a phase I study with defactinib have recently been 
reported (118). Disease stabilization at 12 weeks occurred in 6 
of 37 patients receiving doses ≥200 mg/day. Treatment-related 
adverse events were mild to moderate, and reversible. A recom-
mended phase II dose was defined. Of note, one clinical phase 
II study with defactinib in mesothelioma (NCT01870609) has 
been terminated due to lack of efficacy. Defactinib was also 
compared with a small-molecule FAK scaffolding inhibitor, Y15 
(119). Cell viability was decreased in a dose-dependent manner 
in four thyroid cancer cell lines with Y15 and with higher doses 
of defactinib. Importantly, a combination of the two yielded 
synergistic effects, suggesting the possibility of enhancing effi-
cacy by combining FAK inhibitors that work through different 
mechanisms of action. Defactinib is also being studied in a clini-
cal trial in combination with VS-5584, a dual phosphoinositide 
3-kinase (PI3K)-mammalian target of rapamycin (mTOR) 
inhibitor that will be discussed in the following. VS-4718 is in 
two clinical studies. In preclinical studies, VS-4718 showed 
that cells most sensitive to FAK inhibition lacked expression of 
the neurofibromatosis type 2 tumor suppressor gene product, 
Merlin (120). Merlin expression is often lost in malignant pleural 
mesothelioma. Low Merlin expression predicted for increased 
sensitivity of mesothelioma cells to VS-4718, in vitro and in vivo. 
Moreover, whereas pemetrexed and cisplatin, standard-of-care 
agents for mesothelioma, enrich for CSCs, FAK inhibitor treat-
ment preferentially eliminated these cells.
PF-00562271 is another FAK inhibitor that was investigated in 
clinical studies, but its development has now been discontinued. In 
metastatic docetaxel-resistant prostate cancer cell lines, it reduced 
FAK phosphorylation in the resistant cells without affecting cell 
viability and overcame the chemoresistant  phenotype (134).
Inhibitors of the PI3K–AKT–mTOR Pathway
The first component of this pathway, PI3K, encompasses 
three classes of molecules, with class IA PI3Ks being the most 
deeply investigated in cancer (135). Class IA PI3Ks are acti-
vated by RTKs, G-protein-coupled receptors, and some other 
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post-receptor signaling molecules (e.g., RAS). Activated PI3K 
converts phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] into 
phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3]. PI(3,4,5)
P3 binds and recruits the second pathway component, AKT, to 
the plasma membrane. This process is negatively regulated by 
the tumor suppressor phosphatase and tensin homolog (PTEN), 
which converts PI(3,4,5)P3 back to PI(4,5)P2. AKT is activated 
at the plasma membrane through phosphorylation. Activated 
AKT initiates a cascade of downstream signaling events, which 
promote cellular growth, metabolism, proliferation, survival, 
migration, apoptosis, and angiogenesis. A major downstream 
effector of AKT is mTOR complex (mTORC) 1; its downstream 
targets control protein synthesis. Another mTORC, mTORC2, 
participates in the phosphorylation and activation of AKT (136). 
The PI3K–AKT–mTOR pathway is one of the most frequently 
activated signaling pathways in cancer. The two most common 
mechanisms in human cancers are activation by RTKs and somatic 
mutations in specific components of the signaling pathway (135).
The PI3K–AKT–mTOR pathway is involved in CSC biology in 
several solid tumors and hematological malignancies: leukemias 
(122, 137), breast cancer (138, 139), colon cancer (140), pancre-
atic cancer (85), SCLC (141), glioblastoma (142), and bladder 
cancer (138).
Given the relevance of this pathway in tumorigenesis, it is 
not surprising that the number of compounds that inhibit one 
or more components of these pathways and that are in clinical 
studies is enormous (135). Yet, few of them are being investigated 
as anti-CSC compounds. One is VS-5584, a PI3K/mTOR dual 
inhibitor. It exhibits approximately equal low nanomolar potency 
against mTOR and all PI3K class I isoforms (121). VS-5584 is 
up to 30-fold more potent in inhibiting the proliferation and 
survival of CSCs compared with non-CSCs in solid tumor cell 
populations. It preferentially diminishes CSC levels in mouse 
xenograft models and, ex vivo, in surgically resected breast and 
ovarian patient tumors. VS-5584 delayed tumor regrowth follow-
ing chemotherapy in xenograft models of SCLC. The preferential 
activity on CSCs compared to non-CSCs may explain the limited 
efficacy of PI3K inhibitors used as monotherapies in trials on 
patients with tumors harboring PI3K pathway activation (143). 
VS-5584 is currently in phase I clinical trials in hematological 
and non-hematological malignancies, alone or in combination 
with the FAK inhibitor VS-6063 (Table 3).
BEZ235 is another PI3K/mTOR dual inhibitor that has 
prominent anti-CSC activity (144). Thus, combination of BEZ235 
with radiotherapy effectively increased radiosensitivity of radi-
oresistant prostate cancer cell lines, induced more apoptosis in 
radioresistant cells, reduced the expression of EMT and CSC 
markers and of the PI3K–AKT–mTOR pathway compared with 
radiotherapy alone. The PI3K–AKT–mTOR signaling pathway is 
highly activated also in colon CSCs and inhibition with BEZ235 
suppressed their proliferation (140). BEZ235 has been investi-
gated in numerous clinical studies for its antitumor activity, but 
the development has now been discontinued.
Eventually, also the mTOR inhibitor temsirolimus, which has 
already been approved for the therapy of renal cell carcinoma is 
being evaluated in a phase I/II clinical trial in combination with 
liposomal doxorubicin in patients with advanced soft tissue and 
bone sarcomas. Clinical efficacy and proportion of CSCs before 
and after therapy are some of the outcomes of this study (Table 3).
Inhibitors of the RAS–RAF–MEK–ERK Pathway
The RAS–RAF–MEK-extracellular signal-regulated kinase 
(ERK) signaling pathway is, together with the PI3K–AKT–mTOR 
pathway, one of the most frequently involved in cancer biology. 
In fact, this pathway is hyperactivated in a high percentage of 
tumors, mostly because of the presence of activating mutations of 
the RAS genes (145). Recently, several compounds targeting com-
ponents of this pathway have been approved for the therapy of 
metastatic melanoma and have shown promising clinical activity 
in other tumor types (68, 146). Several preclinical studies showed 
an involvement of this signaling pathway in the CSC biology of 
several tumor types. Thus, deficient expression of a negative regu-
lator, dual specificity phosphatase-4, leads to aberrant activation 
of the pathway with consequent resistance to chemotherapeutics, 
increased mammosphere formation of CD44+/CD24− tumor cells 
in basal-like breast cancer (147). This pathway is also involved in 
the biology of CSCs of several tumor types, such as bladder cancer 
(148), colon cancer (149), and leiomyosarcoma (150). In some 
cases, a coordinate activation of the PI3K–AKT–mTOR and 
RAS–RAF–MEK–ERK has been demonstrated (150, 151). This 
finding is not surprising, given the intimate relationship between 
these two pathways, with RAS being an activating signaling node 
for both pathways (152).
A MEK inhibitor, trametinib (GSK1120212), is being tested in a 
phase II clinical trial in surgically resectable oral cavity squamous 
cell cancer (Table 3). Measurement of changes of CD44+ CSCs 
before and after treatment is one of the outcomes of this study. In 
fact, a preclinical study in a model of head and neck cancer had 
shown that CD44 is a critical target of ERK in promoting tumor 
aggressiveness and proposed this pathway as a target to treat head 
and neck cancer (123).
Inhibitors of Signal Transducer and Activator of 
Transcription 3 and Other Transcription Factors
Signal transducer and activator of transcription (STAT) 3 is a 
transcription factor downstream of several cytokine (e.g., IL-6) 
and growth factor receptors and non-RTKs, such as SRC (153, 
154). STAT3 is frequently overexpressed in carcinomas second-
ary to the activation of upstream kinases (155). It modulates the 
expression of a broad range of downstream genes (156), and 
plays a crucial role in CSC biology in several tumor types, such 
as breast cancer (139), colon cancer (157), endometrial cancer 
(158), prostate cancer (159), lung cancer (160), pancreatic cancer 
(161), and glioblastoma (162).
Napabucasin/BBI608 is a synthetic napthofurandione natural 
product, which was originally extracted from Bignoniaceae 
tabeluia. It inhibits gene transcription driven by STAT3, blocks 
spherogenesis of CSCs, kills CSCs, and downregulates CSC-
associated genes (124). In vivo, BBI608 prevents cancer relapse in 
a pancreatic cancer model and metastasis but completely spares 
hematopoietic stem cells. BBI608 is well tolerated with no signs 
of adverse events in preclinical toxicology studies. BBI608 is 
in phase III clinical trials (Table 3). While BBI608 is the most 
TABLe 4 | inducers of CSC differentiation.
Anti-CSC compound ClinicalTrials.gov identifier 
(phase for the indicated 
trials): Patient population, 
CSC-related outcomes
Reference
Tretinoin NCT02273102 (phase I): with 
tranylcypromine in acute myeloid 
leukemia and myelodysplastic 
syndromes
(166)
Arsenic trioxide NCT01397734 (phase I): 
targeting leukemia stem cells 
with arsenic trioxide and TKIs in 
chronic myeloid leukemia
(167)
Thioridazine NCT02096289 (phase I): with 
intermediate-dose cytarabine 
in older patients with relapsed 
or refractory acute myeloid 
leukemia. Among outcomes: 
assessment of functional 
leukemia stem cells
(168)
CSC, cancer stem-like cell; TKI, tyrosine kinase inhibitor.
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advanced anti-CSC compound in clinical development, there 
are concerns about the specificity of this compound, given its 
quinone structure and potential to exert pleiotropic effects inside 
cells. Risks and opportunities of such promiscuous compounds 
have been recently discussed (163, 164).
The same company is developing also another small-molecule 
inhibitor, BBI503. While no publication is available about this 
inhibitor, it is claimed to inhibit Nanog and other CSC pathways 
by targeting kinases. Nanog is a transcription factor that acts as 
a key regulator of embryonic stem cell maintenance. Nanog is 
dysregulated in cancer and is involved in the maintenance of 
CSCs (125). BBI503 is in several phase I–II clinical studies, and 
two clinical studies are also investigating the combined use of 
BBI608 and BBI503 (Table 3).
Activators of 5′ Adenosine  
Monophosphate-Activated Protein Kinase
While most anti-CSC compounds are inhibitors of pathways that 
are conducive to CSCs, 5′ adenosine monophosphate-activated 
protein kinase (AMPK) acts as an endogenous inhibitor of CSCs 
and, consequently, activators of AMPK are being investigated 
as anti-CSC compounds. The anti-diabetic drug metformin is 
the prototypic member of this class. It inhibits preferentially the 
growth of CSCs compared to the bulk of tumor cells and combi-
natorial therapy with standard chemotherapeutics (doxorubicin, 
paclitaxel, and cisplatin) increases tumor regression and prolongs 
remission in mouse xenografts (126). In addition, metformin can 
decrease the chemotherapeutic dose for prolonging tumor remis-
sion in xenografts of multiple cancer types. Phenformin, a related 
biguanide, is generally considered to represent a stronger version 
of metformin. While the most broadly accepted mechanism of 
action whereby metformin inhibits CSCs is through AMPK acti-
vation and consequent inhibition of PI3K–AKT–mTOR signaling 
(127), other AMPK-independent mechanisms may contribute to 
the antitumor activity of metformin (128, 165). Metformin has 
also been shown to inhibit and reverse EMT in cell lines resistant 
to EGFR tyrosine kinase inhibitors through inhibition of TGF-
β-induced EMT (131) and of the IL-6/STAT3 axis (132). Recent 
results in a non-tumor system have shown that metformin inhibits 
monocyte-to-macrophage differentiation via AMPK-mediated 
inhibition of STAT3 activation (133). These observations estab-
lish a link between AMPK and another crucial pathway in CSC 
biology, STAT3, in addition to PI3K–AKT–mTOR. Metformin 
is now being studied in a large number of clinical trials for its 
antitumor activity, and some of these trials investigate also the 
anti-CSC activity (Table 3).
inducers of CSC Differentiation
The possibility of inducing the differentiation of CSCs into non-
CSC tumor cells appears a logical approach for anti-CSC therapy. 
It is speculated that some of the anti-CSC compounds discussed 
so far act by inducing differentiation of CSCs (98). In the follow-
ing, we discuss some other compounds that act by inducing CSC 
differentiation.
All-trans-retinoic acid/tretinoin is currently used for the 
therapy of acute promyelocytic leukemia (APL), a subtype 
of AML, where it induces differentiation of leukemic blasts. 
However, among patients with non-APL AML, tretinoin-based 
treatment has not been effective. It has now been shown that, 
through epigenetic reprograming, inhibitors of lysine-specific 
demethylase 1, including tranylcypromine, unlock the tretinoin-
driven therapeutic response in non-APL AML (166). Treatment 
with tretinoin plus tranylcypromine markedly diminished the 
engraftment of primary human AML cells in vivo in immuno-
deficient mice, suggesting that tretinoin in combination with 
tranylcypromine may target leukemia CSCs. This therapeutic 
combination is now being studied in a phase I clinical trial in 
AML patients (Table 4).
Also arsenic trioxide is used for the therapy of APL where it 
induces differentiation and apoptosis of leukemic cells. Arsenic 
trioxide has now been reported to induce differentiation of HCC 
CSCs by downregulating the expression of CD133 and other CSC 
markers (167). The self-renewal ability and tumorigenic capacity, 
but not the proliferation in vitro, were inhibited. In vivo, arsenic 
trioxide decreased recurrence rates after radical resection and 
prolonged survival in a mouse model. Arsenic trioxide is being 
studied, in combination with tyrosine kinase inhibitors in a clini-
cal trial for its capacity to target the CML stem cell population 
(Table 4).
Thioridazine is an antipsychotic drug that antagonizes 
dopamine receptors. It was identified using a discovery platform 
that reveals differences between neoplastic and normal human 
stem cells in undergoing differentiation in response to molecules 
from libraries of known compounds (168). Thioridazine was 
found to selectively target neoplastic cells, and to impair human 
somatic CSCs capable of in vivo leukemic disease initiation while 
having no effect on normal blood stem cells. Thioridazione is 
now undergoing a phase I trial in combination with cytarabine 
in patients with AML. Objective response rates and effects on 
TABLe 5 | Anti-CSC compounds with undefined mechanism of action or targeting diverse signaling pathways.
Anti-CSC compound ClinicalTrials.gov identifier (phase for the indicated trials): patient population,  
CSC-related outcomes
Reference
Disulfiram NCT01777919 (phase II): disulfiram and copper with chemotherapy in the treatment of newly 
diagnosed glioblastoma
(59, 129, 130, 165, 
180, 181)
Chloroquine NCT01023477 (phase I/II): testing whether chloroquine reduces the ability of ductal 
carcinoma in situ to survive and spread. Among outcomes: effect on progenitor cell yield and 
invasive capacity ex vivo
(182, 183)
Oncolytic adenovirus NCT01956734 (phase I): with temozolomide for treatment of glioblastoma – combination 
effective in killing glioblastoma CSCs
(184)
CSC, cancer stem-like cell.
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leukemic stem cells are among the outcomes of this study (see 
Table 4).
Radiotherapeutic Targeting of  
CSC-enriched Domains
CSCs are resistant to radiation because of enhanced self-renewal 
capacity, DNA-repair capacity, and enhanced reactive oxygen 
species defenses. In spite of this radioresistance, new radio-
therapeutic approaches appear to be promising treatments for the 
targeting of CSCs (169). Moreover, it is currently believed that 
glioblastoma CSCs derive from the transformation of normal 
tissue stem cells residing in the subventricular zones of the brain 
(170). This finite anatomic location of the glioblastoma CSC 
pool has suggested the possibility of targeting these cells with 
radiotherapeutic approaches. One clinical trial investigating the 
effects of radiotherapy to brain areas containing CSCs in com-
bination with temozolomide in glioblastoma patients is ongoing 
(NCT02039778, phase I/II).
Anti-CSC Compounds with Undefined 
Mechanism(s) of Action or Targeting 
Diverse Signaling Pathways
Salinomycin
Salinomycin is the first molecule that was found to have anti-
CSC activities. It was identified in a chemical screen that had 
been designed to discover compounds showing selective toxicity 
for breast CSCs (171). Salinomycin has been widely used as an 
anticoccidiosis agent in chickens. It is a natural, fused polypyran 
ionophore able to shield charge of ions and to cross cell lipid 
membranes, thereby interfering with transmembrane potassium 
potential and promoting mitochondrial and cellular potassium 
flux. Salinomycin is a complex natural molecule produced by 
fermentation with many stereocenters. Efforts are underway to 
develop synthetic salinomycin analogs. Salinomycin reduced the 
proportion of CSCs by >100-fold relative to paclitaxel, inhibited 
mammary tumor growth in vivo and reduced expression of breast 
CSC genes. Ionic changes induced by salinomycin were found 
to inhibit proximal WNT signaling by interfering with phospho-
rylation of the WNT coreceptor LPR6 (172). In the following, 
salinomycin has also been found to modulate Hh signaling (173), 
to induce accumulation of reactive oxygen species (174), and 
inhibit STAT3 activation (175). In general, compounds endowed 
with a pleiotropic array of mechanisms of action are, clinically, 
of little promise. Nevertheless, salinomycin has been reported 
being investigated in clinical trials (176), but these trials are not 
reported under the clinicaltrials.gov website.
Disulfiram
This is a dithiocarbamate used for the treatment of chronic 
alcoholism where it produces acute sensitivity to ethanol due 
to its inhibitory activity on ALDH (177). Disulfiram was found 
to possess antitumor activity in early clinical studies (178) and, 
in recent years, to possess anti-CSC activities. Thus, disulfiram 
inhibits TGF-β-induced EMT and CSC-like features in breast 
cancer cells (179). It can also inhibit the proliferation and self-
renewal of glioblastoma CSCs (180). Regarding the mechanism 
of action, disulfiram can act as a proteasome inhibitor and this, in 
turn, inhibits nuclear translocation and DNA-binding activity of 
NF-κB (130). Moreover, being an irreversible inhibitor of ALDH, 
disulfiram might also act as an inhibitor of ALDH-positive CSCs 
(129). Disulfiram is now being investigated in clinical studies, 
and the results of a preliminary clinical trial appear encouraging 
(181). In one study, it is used in combination with temozolomide 
in newly diagnosed glioblastoma (Table  5). This study refers 
explicitly to the anti-CSC activity of disulfiram.
Chloroquine
Chloroquine has anti-CSC activity (182), and this effect is con-
sidered to be the consequence of the lysosomotropic action of 
chloroquine and consequent inhibition of autophagy. Balic et al. 
(183), however, have found that chloroquine targets pancreatic 
CSCs through a dual mechanism of action: first, inhibition of CXC 
ligand 12/CXCR4 signaling, resulting in reduced phosphorylation 
TABLe 6 | Anti-CSC vaccines.
Molecular target, anti-CSC compound ClinicalTrials.gov identifier (phase): clinical trial indication Reference
CSC-loaded DCs NCT02178670, NCT02074046, NCT02115958, NCT02084823, NCT02089919, 
NCT02176746, NCT02063893 (phase I/II): vaccination against ovarian cancer, 
pancreatic cancer, nasopharyngeal cancer, lung cancer, HCC, CRC, breast cancer
(188)
Multiantigen DNA plasmid-based vaccine NCT02157051 (phase I): in HER2-negative advanced stage breast cancer
Stem cell, tumor-amplified RNA loaded on DCs NCT00890032 (phase I): in patients undergoing surgery for recurrent glioblastoma 
multiforme
DCs transfected with CSC-derived mRNA NCT00846456 (phase I/II): in patients receiving standard therapy for glioblastoma (191)
Autologous DCs pulsed with lysate from an allogeneic 
glioblastoma CSC line
NCT02010606 (phase I): in newly diagnosed or recurrent glioblastoma. Among 
outcomes: assessment of CSC antigen expression
DCs loaded with glioma CSCs-associated antigens NCT01567202 (phase II): in glioblastoma multiforme. (192)
DCs loaded with brain tumor CSCs NCT01171469 (phase I): in recurrent or progressive malignant gliomas
Peptides WT1: 126–134 and PRI:169–177, found in 
leukemic stem cells, in MontanideTM and administered 
with GM-CSF
NCT00488592 (phase II): in low risk myeloid malignancies (193)
CRC, colorectal cancer; CSC, cancerstem-like cell; DC, dendritic cell; GM-CSF, garnulocyte-macrophage colony-stimulating factor; HER, human epidermal growth factor; HCC, 
hepatocellular carcinoma.
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of ERK and STAT3. Second, chloroquine inhibited Hh signaling 
by decreasing the production of SMO, translating into down-
regulation of downstream targets in CSCs and the surrounding 
stroma. Chloroquine-induced inhibition of STAT3 signaling as 
a mechanism for the anti-CSC activity of chloroquine has been 
reported also by Choi et  al. (185). Chloroquine is currently 
being investigated in clinical studies for its anti-CSC activity (see 
Table 5).
Oncolytic Adenovirus
The tumor-selective oncolytic adenovirus Delta-24-RGD has 
antiglioma effects (186) and overcomes temozolomide resistance 
by silencing the O6-methylguanine-DNA methyltransferase 
promoter (187). Delta-24-RGD infects, replicates, and induces 
autophagic cell death in brain CSCs (184). It is being studied 
in combination with temozolomide in a phase I clinical trial in 
glioblastoma patients (Table 5).
vaccination Against CSCs
Vaccination against CSCs or individual proteins overexpressed in 
CSCs is another anti-CSC approach. In preclinical studies, synge-
neic hosts have been immunized with CSC-enriched populations 
(188). This source was more effective than unselected tumor 
cells in inducing protective antitumor immunity. Immune sera 
from vaccinated hosts contained lytic anti-CSC IgG antibodies, 
and cytotoxic T-lymphocytes that were capable of killing CSCs 
in vitro.
Recently, anti-CSC vaccination against individual proteins 
has been proposed. Sox2 is a transcription factor required for the 
maintenance of normal neural stem cells and for the biology of 
oligodendroglioma CSCs. Immunization of mice with Sox2 pep-
tides delayed tumor development and prolonged survival (189). 
In another study, xCT, the functional subunit of the cystine/glu-
tamate antiporter system xc-, has been found to be upregulated 
in mammospheres derived from murine human EGFR2-positive 
breast tumor cells (190). Downregulation of xCT impaired mam-
mosphere generation and altered CSC intracellular redox balance 
in  vitro. DNA vaccination-based immunotargeting of xCT in 
mice delayed subcutaneous growth of mammophere-derived 
cells, impaired pulmonary metastasis formation, and increased 
CSC chemosensitivity to doxorubicin in vivo. Table 6 lists ongo-
ing clinical trials aimed at vaccinating tumor-bearing patients 
against CSCs.
Looking Ahead – 1. epigenetic Drugs 
for Anti-CSC Therapy
Epigenetic reprograming is a characteristic trait of tumorigen-
esis and CSC biology. Reprograming has been demonstrated for 
every component of the epigenetic machinery, including DNA 
methylation, histone modifications, nucleosome positioning, 
and non-coding RNAs, specifically microRNA expression (194). 
The possibility of therapeutically manipulating these events is 
attractive because cancer-associated epigenetic aberrations are 
reversible. Not surprisingly, drug discovery in epigenetics is being 
widely pursued and four epigenetic drugs have already received 
FDA approval (azacitidine, decitabine, vorinostat, and romidep-
sin). Inhibition of CSCs with epigenetic drugs has been demon-
strated in several instances (195–197), and this is likely to become 
a rapidly progressing domain. A note of caution to be sounded for 
these drugs comes from the knowledge that some epigenetic drugs 
have been reported to have tumor-promoting or tumor-inhibiting 
activities in a context-dependent manner (31, 194).
Looking Ahead – 2. improving Tumor 
Delivery of Anti-CSC Medicines
CSCs are often reported to be concealed in hypoxic tumor areas 
(198), and these areas pose significant problems for drug penetra-
tion (199). Therefore, administration of anti-CSC compounds 
may not achieve complete depletion of CSCs present at any 
given time, because of inadequate tumor penetration. Moreover, 
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inadequate penetration of antitumor drugs may contribute to 
the induction of drug resistance (200). Therefore, improving the 
delivery of anti-CSC compounds to their target cells has become 
an area of active research (201). In general, one can envisage two 
main approaches. First, through the use of passively or actively 
targeted nanoparticles (202). Second, through coadministration 
of promoter drugs that facilitate the penetration of compounds 
endowed with direct antitumor effects (the effector drug) (199, 
203). While none of these approaches has yet made its way to the 
clinic, several preclinical studies suggest their feasibility. Thus, 
PEGylated polymeric micelles were loaded with salinomycin to 
effectively target breast CSCs and shown to be more effective than 
salinomycin in vivo (204). Others demonstrated that nanopar-
ticles can penetrate, upon convection-enhanced delivery, large 
intracranial volumes in experimental animals. When loaded 
into these nanoparticles, a compound that had been identified 
possessing anti-CSC activity, ditiazanine iodide, significantly 
increased survival in rats bearing brain CSC-derived xenografts 
(205).
Regarding the possibility of improving the penetration of 
effector drugs through the coadministration of a promoter drug, 
it is interesting to note that an anti-CSC compound that has been 
discussed above, IPI-926, a Hh pathway inhibitor, has been shown 
to improve penetration of an effector drug (gemcitabine) into 
pancreatic tumors through depletion of tumor-associated stro-
mal tissue (206). In fact, paracrine Hh signaling from neoplastic 
cells promotes stromal desmoplasia (207). Combined with their 
anti-CSC activity, compounds of this class may be of particular 
interest because they have the potential to combine in a single 
molecule anti-CSC activity and promotion of tumor penetration.
ANTi-CSC COMPOUNDS iN CLiNiCAL 
DeveLOPMeNT – A CRiTiCAL APPRAiSAL
There are several crucial points to address when taking an overall 
look to anti-CSC compounds in current clinical investigation.
The first, most important and most difficult point to answer 
is how to evidence clinical benefit that may derive from anti-
CSC compounds. Currently used antitumor drugs target mainly 
proliferating tumor cells, while sparing CSCs and even inducing 
the generation of new CSCs. On the other hand, anti-CSC com-
pounds are inactive against the bulk of proliferating tumor cells 
because they target markers or pathways that are overexpressed 
or selectively expressed on CSCs compared to bulk tumor cells. 
Consequently, the vast majority of ongoing clinical trials with 
anti-CSC compounds are performed in combination with other 
antitumor drugs belonging to different classes of compounds. 
Therefore, the easiest way to answer the question as to how evi-
dence clinical benefit it to say that anti-CSC compounds should 
improve the efficacy of anti-cancer therapies that are given in 
combination, i.e., higher percentages of patients with clinical 
responses or stable disease for longer periods of time than patients 
treated with standard-of-care therapies. This, however, is the goal 
of any anti-cancer therapy, whether or not targeting CSCs. So, 
the question arises as to how it is possible to recognize bona fide 
anti-CSC activity compared to generic antitumor effects.
A first possibility, and probably also the most realistic, is to 
state that any clinical benefit deriving from anti-CSC therapy 
should be accompanied by a decline of tumor tissue CSCs or 
circulating CSCs (208). Not surprisingly, many clinical trials 
with anti-CSC compounds include, among the study outcomes, 
the determination of tumor tissue or circulating CSCs (see the 
tables throughout this article). In fact, it is not obvious that anti-
CSC compounds exert antitumor effects through their anti-CSC 
activity, because most, if not all of them, are not CSC-specific. 
One example is represented by anti-DLL4 antibodies. While one 
anti-DLL4 antibody is being developed as an anti-CSC compound 
(79), a second antibody is being developed as an anti-angiogenic 
compound (108), and anti-DLL4 antibodies have even been 
shown to exert antitumor effects by acting on cells of the tumor 
stroma (107).
In spite of such a pharmacodynamic approach it would be, 
nevertheless, desirable to identify the clinical setting that would 
profit most from anti-CSC therapy. If we consider that CSCs 
replenish the bulk of proliferating tumor cells, then anti-CSC 
compounds should be most efficacious after debulking of tumor 
cells, i.e., in an adjuvant setting. In fact, in tumors that do not 
display HER2 gene amplification, HER2 may be selectively 
expressed on CSCs, and an anti-HER2 antibody blocked growth 
of these HER2-negative tumors in mouse models when admin-
istered in the adjuvant setting but had no effect on established 
tumors (209). Given that, it is somehow surprising to note that 
there are no ongoing clinical trials studying anti-CSC compounds 
in an adjuvant setting. Only one study evaluates the expression of 
a CSC marker as a predictor of adjuvant chemotherapy response 
in breast cancers of high-risk women (NCT00949013). A likely 
reason for this attitude is that the execution of clinical trials in 
an adjuvant setting is challenging for most tumor types, both in 
terms of duration and costs.
Another question is as to which molecular targets should 
be addressed in order to have the greatest chances of success. 
Although, also in this case, only results from clinical practice will 
give definitive answers, some guidelines may help in taking the 
most promising roads. First, going through the pathways that are 
involved in CSC biology and are targets for anti-CSC compounds, 
it can be appreciated that none of these pathways or targets have 
been clearly attributed to a single tumor type or subtype. This 
implies that in each tumor several of these pathways can be active, 
i.e., the system appears highly redundant and prone to native and 
acquired resistance. There are several possibilities to mitigate 
these consequences.
First, using a given anti-CSC compound only when aberrant 
activation of the relevant pathway is clearly demonstrated. This is 
important not only for avoiding native drug resistance and delay-
ing insurgence of acquired drug resistance, but also because some 
of the pathways that are being targeted for anti-CSC therapy play 
a context-dependent tumor- and CSC-promoting role, while, in 
a different context, they may also exert tumor-suppressive effects. 
There are several examples of these opposite, context-dependent 
effects, for example, the Notch (210, 211), TGF-β (212), WNT 
(82, 213), and STAT3 (214) pathways.
Second, using anti-CSC compounds that are directly 
cytotoxic, such as ADCs or native antibodies that act 
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through antibody-dependent cellular cytotoxicity or 
 complement-dependent cytotoxicity. Use of these compounds 
does not exclude the possibility of selecting for cells that are 
mutated in the epitope recognized by the targeting moiety, as has 
been elegantly demonstrated in a recent work (215). Nevertheless, 
these compounds are expected to be less conducive to resistance 
than anti-CSC compounds that inhibit signaling pathways with-
out being directly cytotoxic. In fact, these latter compounds may 
themselves promote acquisition of drug resistance when acting 
on cells at suboptimal concentrations like those that are achieved 
in hypoperfused tumor domains (200).
A further turn of complexity is given by the fact that, in 
any given tumor and at any given time, CSCs may represent a 
heterogeneous population, both functionally and phenotypically 
(116, 216). This fact, taken together with the redundancy of the 
signaling systems underlying CSC biology, suggests that the com-
bined use of anti-CSC compounds may represent still another 
approach to mitigate untoward consequences. Thus, combined 
use of different anti-CSC compounds may embrace a larger part 
of the whole CSC population than a single compound. Preclinical 
studies suggest that, indeed, combined use of anti-CSC com-
pounds is more efficacious than their individual use (85, 217), 
and, as already mentioned before in this article, clinical studies 
with combinations of anti-CSC compounds are ongoing.
Another last point to consider is the plasticity of CSCs. We have 
already discussed the role of stimuli from the tumor micronevi-
ronment in CSC biology. These stimuli are the result of unlimited 
tumor cell proliferation that causes the generation of different 
forms of stressors, which, in combination with the inherent genetic 
instability of tumor cells, shapes the CSC landscape. The implicit 
consequence of this is that once tumor cells resume growth after 
drug-induced depletion, the same conditions that generated the 
CSC-inducing stimuli will be recreated and give rise again to a 
CSC population. Therefore, anti-CSC therapy should not be 
expected to act as a device that leads, in combination with other 
antitumor therapies, to tumor eradication but, rather, as a tool to 
improve the clinical efficacy of existing drugs. The ongoing clinical 
trials will tell us in the next years if this is a feasible goal to achieve.
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